Liraglutide (Victoza) Research Overview (also known as Victoza, Saxenda, NN2211, Liraglutide acetate)
Liraglutide is a long-acting GLP-1 receptor agonist with 97% homology to native human GLP-1, administered via once-daily subcutaneous injection for type 2 diabetes management (Victoza) and chronic weight management (Saxenda at 3mg). It reduces blood glucose through multiple mechanisms including glucose-dependent insulin stimulation, glucagon suppression, and delayed gastric emptying. Clinical trials demonstrate significant cardiovascular benefits alongside 5-8% average body weight reduction.
What Is Liraglutide (Victoza)?
Liraglutide is a synthetic, long-acting analogue of human glucagon-like peptide-1, or GLP-1, a hormone produced primarily by intestinal L cells after food intake. It has approximately 97% amino-acid sequence identity with native human GLP-1. Structural modifications, including substitution of an amino acid and attachment of a fatty-acid side chain, increase albumin binding and slow enzymatic degradation by dipeptidyl peptidase-4. These changes extend its circulating half-life to approximately 13 hours, allowing once-daily subcutaneous administration rather than the very short exposure associated with endogenous GLP-1.
Liraglutide was developed by Novo Nordisk and received United States Food and Drug Administration approval as Victoza in 2010 for improving glycemic control in adults with type 2 diabetes; pediatric use was subsequently expanded in selected age groups. The 3-mg formulation, marketed as Saxenda, was approved in 2014 as an adjunct to reduced-calorie nutrition and increased physical activity for chronic weight management in adults with obesity or overweight accompanied by weight-related health conditions. Liraglutide is related to, but pharmacokinetically different from, semaglutide: liraglutide is generally injected daily and has a half-life of about 13 hours, whereas semaglutide is formulated for weekly administration and has a half-life of approximately one week. Both activate the GLP-1 receptor, but dose, exposure profile, clinical outcomes, and tolerability are not interchangeable. Liraglutide remains important in metabolic research involving appetite regulation, beta-cell physiology, cardiovascular risk, fatty liver disease, and neurodegenerative mechanisms.
Victoza and Saxenda contain the same active molecule but are approved, labeled, and dosed for different indications. Victoza is used at doses up to 1.8 mg daily for type 2 diabetes, while Saxenda is titrated to 3 mg daily for obesity treatment. Neither product should be used as a substitute for the other without clinical supervision. The term research use may refer either to investigation of approved clinical treatment or to laboratory study of GLP-1 biology; it does not imply that unsupervised use of prescription liraglutide or nonapproved formulations is safe.
Research Indications
Glycemic Control
Type 2 diabetes HbA1c reduction
Large randomized trials support clinically meaningful HbA1c reductions when liraglutide is used with diet, activity, and background glucose-lowering therapy.
Fasting and postprandial glucose
GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying.
Cardiovascular Risk Reduction
Major adverse cardiovascular events
In the LEADER cardiovascular outcomes trial, liraglutide reduced the composite risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in high-risk type 2 diabetes.
Cardiovascular mortality
Evidence from the outcomes trial supports a reduction in cardiovascular death among patients with established cardiovascular risk.
Body Weight and Appetite
Weight loss with lifestyle intervention
Liraglutide can reduce body weight through appetite and energy-intake effects; weight-focused research commonly uses the higher 3 mg liraglutide regimen marketed separately as Saxenda.
Reduced hunger and food intake
Central and gastrointestinal GLP-1 signaling is associated with increased satiety, reduced hunger, and smaller spontaneous energy intake in clinical studies.
Prediabetes and Diabetes Delay
Delay of type 2 diabetes onset
A long-term trial in people with obesity and prediabetes found fewer diagnoses of type 2 diabetes during treatment with 3 mg liraglutide plus lifestyle intervention.
Metabolic risk-factor improvement
Changes in weight, glycemia, and some cardiometabolic measures have been observed, but applicability depends on population, dose, and concurrent lifestyle treatment.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Tolerability initiation | 0.6 mg | Once daily for 1 week | Subcutaneous |
| Type 2 diabetes maintenance | 1.2 mg | Once daily | Subcutaneous |
| Additional glycemic control | 1.8 mg | Once daily | Subcutaneous |
| Weight-management research | Up to 3.0 mg | Once daily; separate product indication | Subcutaneous |
Timing
Administer once daily at any time of day, independently of meals, using the abdomen, thigh, or upper arm with site rotation. Standard labeling uses weekly titration to reduce gastrointestinal effects; do not alter prescribed dosing without clinician guidance.
Peptide Interactions
Concomitant use can increase hypoglycemia risk. Insulin dose adjustment and glucose monitoring may be required under prescriber supervision.
Agents such as glimepiride can add hypoglycemia risk when combined with liraglutide; background sulfonylurea reduction may be considered clinically.
This is a commonly studied combination for type 2 diabetes, with complementary mechanisms and generally low intrinsic hypoglycemia risk absent insulin or secretagogues.
Do not combine with another GLP-1 receptor agonist; overlapping therapy is not recommended and may increase adverse gastrointestinal effects without established benefit.
Delayed gastric emptying and dietary change can complicate oral drug management; closer INR monitoring is prudent when therapy is initiated or changed.
Liraglutide delays gastric emptying and may affect the rate of absorption of some oral medicines; review narrow-therapeutic-index drugs with a clinician or pharmacist.
Reported Research Timeline
01Days 1–7 (reported in cited studies): initiation at 0.6 mg is intended primarily to improve gastrointestinal tolerability. Nausea, reduced appetite, early satiety, constipation, or diarrhea may occur.
02Weeks 2–4 (reported in cited studies): dose escalation may occur if tolerated. Appetite effects and improved fasting glucose can become more apparent; gastrointestinal symptoms often lessen with slower titration.
03Weeks 4–12 (reported in cited studies): consistent daily exposure may produce measurable changes in fasting and postprandial glucose. Weight change is variable and depends strongly on dietary intake and activity.
04Around 3 months: HbA1c response is commonly assessed after sufficient time at a stable maintenance dose. Clinicians may review glucose logs, body weight, tolerability, and adherence.
05Months 3–6 (reported in cited studies): longer-term glycemic, weight, blood-pressure, and treatment-tolerability trends can be evaluated. Background diabetes medications may need adjustment to avoid hypoglycemia.
06Ongoing (reported in cited studies): continue periodic monitoring of glycemic control, renal status when clinically indicated, injection technique, and symptoms suggestive of gallbladder or pancreatic disease.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Common effects include nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite, and headache; these are often most prominent during dose escalation.
Use caution with insulin or sulfonylureas because hypoglycemia risk comes primarily from these concomitant glucose-lowering medicines.
Vomiting or diarrhea can contribute to dehydration and may worsen kidney function, especially in people with pre-existing renal impairment.
Avoid use in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Discuss prior pancreatitis, gallbladder disease, severe gastrointestinal disease, pregnancy planning, and all current medicines with a licensed clinician before treatment.
Seek Medical Attention If:
You develop persistent, severe abdominal pain that may radiate to the back, with or without vomiting, which can indicate pancreatitis.
You have upper abdominal pain, fever, jaundice, or clay-colored stools, which may suggest gallbladder disease.
You experience facial or throat swelling, trouble breathing, widespread rash, fainting, or other signs of a serious allergic reaction.
You have repeated vomiting, cannot maintain fluids, markedly reduced urination, confusion, or symptoms of severe hypoglycemia such as seizure or loss of consciousness.
Quality Indicators
Verified Marker
Authorized presentation and traceable supply
Prefer regulator-authorized, pharmacy-dispensed pens with a verifiable national drug code or equivalent identifier, lot number, and expiration date.
Verified Marker
Clear, colorless solution
The solution should be clear and colorless. Do not use a pen containing particles, cloudiness, discoloration, leakage, or visible damage.
Verified Marker
Intact labeled pen device
Inspect for intact tamper features, readable product strength, matching lot and expiration information, and a functioning dose selector.
Acceptable Range
Documented cold-chain handling
Unopened pens are generally refrigerated; storage allowances after first use depend on the approved local product labeling. Confirm temperature history when supply integrity is uncertain.
Quality Concern
Unverified compounded or gray-market material
Avoid products with no traceable pharmacy source, missing lot information, unclear concentration, broken refrigeration history, or labels that do not identify liraglutide and its approved strength.
Research Citations
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al., 2016, New England Journal of Medicine - A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al., 2015, New England Journal of Medicine - 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
le Roux, C. W., Astrup, A., Fujioka, K., et al., 2017, The Lancet - Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, double-blind, double-dummy, active comparator, parallel-group study
Pratley, R. E., Nauck, M., Bailey, T., et al., 2010, The Lancet - Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Garber, A., Henry, R., Ratner, R., et al., 2009, Diabetologia
Research Focus
GLP-1 receptor agonist, weight loss, type 2 diabetes, cardiovascular protection, appetite suppression, insulin secretion
Frequently Asked Questions
What should researchers watch for with Liraglutide (Victoza)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Liraglutide (Victoza)?
Days 1–7 (reported in cited studies): initiation at 0.6 mg is intended primarily to improve gastrointestinal tolerability. Nausea, reduced appetite, early satiety, constipation, or diarrhea may occur.
How is Liraglutide (Victoza) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →